Immunocore and Pulse Infoframe, Inc. Partner with Leading Academic Institutions to Launch First Global Patient Registry for Uveal Melanoma
(OXFORD, England & CONSHOHOCKEN, Pa. & ROCKVILLE, Md. & ONTARIO, Canada, 18 July 2019) Immunocore Limited, a leading T cell receptor biotechnology company, and Pulse Infoframe, Inc. (Pulse), a data aggregation and analytics company, today announce plans to support the first global patient registry in uveal melanoma (UM), a rare and aggressive form of melanoma, which affects the eye, typically has a poor prognosis and for which there is no currently accepted optimal management or treatment.[i] The insights gained through the academic registry will provide a more comprehensive understanding of the disease and may help to shape the way future research is conducted.